2009R1223 — EN — 10.08.2016 — 012.001

This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document

►B REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance) (OJ L 342 22.12.2009, p. 59)

Amended by:





Corrected by:









▼B

REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 30 November 2009

on cosmetic products

(recast)

(Text with EEA relevance)







CHAPTER I

SCOPE, DEFINITIONS

Article 1

Scope and objective

This Regulation establishes rules to be complied with by any cosmetic product made available on the market, in order to ensure the functioning of the internal market and a high level of protection of human health.

Article 2

Definitions

1. For the purposes of this Regulation, the following definitions shall apply:

(a) ‘cosmetic product’ means any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours;

(b) ‘substance’ means a chemical element and its compounds in the natural state or obtained by any manufacturing process, including any additive necessary to preserve its stability and any impurity deriving from the process used but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition;

(c) ‘mixture’ means a mixture or solution composed of two or more substances;

(d) ‘manufacturer’ means any natural or legal person who manufactures a cosmetic product or has such a product designed or manufactured, and markets that cosmetic product under his name or trademark;

(e) ‘distributor’ means any natural or legal person in the supply chain, other than the manufacturer or the importer, who makes a cosmetic product available on the Community market;

(f) ‘end user’ means either a consumer or professional using the cosmetic product;

(g) ‘making available on the market’ means any supply of a cosmetic product for distribution, consumption or use on the Community market in the course of a commercial activity, whether in return for payment or free of charge;

(h) ‘placing on the market’ means the first making available of a cosmetic product on the Community market;

(i) ‘importer’ means any natural or legal person established within the Community, who places a cosmetic product from a third country on the Community market;

(j) ‘harmonised standard’ means a standard adopted by one of the European standardisation bodies listed in Annex I to Directive 98/34/EC of the European Parliament and of the Council of 22 June 1998 laying down a procedure for the provision of information in the field of technical standards and regulations and of rules on information society services ( 1 ) on the basis of a request made by the Commission in accordance with Article 6 of that Directive;

(k) ‘nanomaterial’ means an insoluble or biopersistant and intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm;

(l) ‘preservatives’ means substances which are exclusively or mainly intended to inhibit the development of micro-organisms in the cosmetic product;

(m) ‘colorants’ means substances which are exclusively or mainly intended to colour the cosmetic product, the body as a whole or certain parts thereof, by absorption or reflection of visible light; in addition, precursors of oxidative hair colorants shall be deemed colorants;

(n) ‘UV-filters’ means substances which are exclusively or mainly intended to protect the skin against certain UV radiation by absorbing, reflecting or scattering UV radiation;

(o) ‘undesirable effect’ means an adverse reaction for human health attributable to the normal or reasonably foreseeable use of a cosmetic product;

(p) ‘serious undesirable effect’ means an undesirable effect which results in temporary or permanent functional incapacity, disability, hospitalisation, congenital anomalies or an immediate vital risk or death;

(q) ‘withdrawal’ means any measure aimed at preventing the making available on the market of a cosmetic product in the supply chain;

(r) ‘recall’ means any measure aimed at achieving the return of a cosmetic product that has already been made available to the end user;

(s) ‘frame formulation’ means a formulation which lists the category or function of ingredients and their maximum concentration in the cosmetic product or gives relevant quantitative and qualitative information whenever a cosmetic product is not covered or only partially covered by such a formulation. The Commission shall provide indications for the establishment of the frame formulation and adapt them regularly to technical and scientific progress.

2. For the purposes of point (a) of paragraph 1, a substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product.

3. In view of the various definitions of nanomaterials published by different bodies and the constant technical and scientific developments in the field of nanotechnologies, the Commission shall adjust and adapt point (k) of paragraph 1 to technical and scientific progress and to definitions subsequently agreed at international level. That measure, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).







CHAPTER II

SAFETY, RESPONSIBILITY, FREE MOVEMENT

Article 3

Safety

A cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use, taking account, in particular, of the following:

(a) presentation including conformity with Directive 87/357/EEC;

(b) labelling;

(c) instructions for use and disposal;

(d) any other indication or information provided by the responsible person defined in Article 4.

The provision of warnings shall not exempt persons defined in Articles 2 and 4 from compliance with the other requirements laid down in this Regulation.

Article 4

Responsible person

1. Only cosmetic products for which a legal or natural person is designated within the Community as ‘responsible person’ shall be placed on the market.

2. For each cosmetic product placed on the market, the responsible person shall ensure compliance with the relevant obligations set out in this Regulation.

3. For a cosmetic product manufactured within the Community, and not subsequently exported and imported back into the Community, the manufacturer established within the Community shall be the responsible person.

The manufacturer may designate, by written mandate, a person established within the Community as the responsible person who shall accept in writing.

4. Where, for a cosmetic product manufactured within the Community, and not subsequently exported and imported back into the Community, the manufacturer is established outside the Community, he shall designate, by written mandate, a person established within the Community as the responsible person who shall accept in writing.

5. For an imported cosmetic product, each importer shall be the responsible person for the specific cosmetic product he places on the market.

The importer may, by written mandate, designate a person established within the Community as the responsible person who shall accept in writing.

6. The distributor shall be the responsible person where he places a cosmetic product on the market under his name or trademark or modifies a product already placed on the market in such a way that compliance with the applicable requirements may be affected.

The translation of information relating to a cosmetic product already placed on the market shall not be considered as a modification of that product of such a nature that compliance with the applicable requirements of this Regulation may be affected.

Article 5

Obligations of responsible persons

1. Responsible persons shall ensure compliance with Articles 3, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, Article 19(1),(2) and (5), as well as Articles 20, 21, 23 and 24.

2. Responsible persons who consider or have reason to believe that a cosmetic product which they have placed on the market is not in conformity with this Regulation shall immediately take the corrective measures necessary to bring that product into conformity, withdraw it or recall it, as appropriate.

Furthermore, where the cosmetic product presents a risk to human health, responsible persons shall immediately inform the competent national authorities of the Member States in which they made the product available and of the Member State in which the product information file is readily accessible, giving details, in particular, of the non-compliance and of the corrective measures taken.

3. Responsible persons shall cooperate with these authorities, at the request of the latter, on any action to eliminate the risks posed by cosmetic products which they have made available on the market. In particular, responsible persons shall, further to a reasoned request from a competent national authority, provide it with all the information and documentation necessary to demonstrate the conformity of specific aspects of the product, in a language which can be easily understood by that authority.

Article 6

Obligations of distributors

1. In the context of their activities, when making a cosmetic product available on the market, distributors shall act with due care in relation to applicable requirements.

2. Before making a cosmetic product available on the market distributors shall verify that:

— the labelling information provided for in Article 19(1)(a), (e) and (g) and Article 19(3) and (4) is present,

— the language requirements provided for in Article 19(5) are fulfilled,

— the date of minimum durability specified, where applicable under Article 19(1), has not passed.

3. Where distributors consider or have reason to believe that:

— a cosmetic product is not in conformity with the requirements laid down in this Regulation, they shall not make the product available on the market until it has been brought into conformity with the applicable requirements,

— a cosmetic product which they have made available on the market is not in conformity with this Regulation, they shall make sure that the corrective measures necessary to bring that product into conformity, withdraw it or recall it, as appropriate, are taken.

Furthermore, where the cosmetic product presents a risk to human health, distributors shall immediately inform the responsible person and the competent national authorities of the Member States in which they made the product available, giving details, in particular, of the non-compliance and of the corrective measures taken.

4. Distributors shall ensure that, while a product is under their responsibility, storage or transport conditions do not jeopardise its compliance with the requirements set out in this Regulation.

5. Distributors shall cooperate with competent authorities, at the request of the latter, on any action to eliminate the risks posed by products which they have made available on the market. In particular, distributors shall, further to a reasoned request from a competent national authority, provide it with all the information and documentation necessary to demonstrate the conformity of the product with the requirements listed under paragraph 2, in a language which can be easily understood by that authority.

Article 7

Identification within the supply chain

At the request of a competent authority:

— responsible persons shall identify the distributors to whom they supply the cosmetic product,

— the distributor shall identify the distributor or the responsible person from whom, and the distributors to whom, the cosmetic product was supplied.

This obligation shall apply for a period of three years following the date on which the batch of the cosmetic product was made available to the distributor.

Article 8

Good manufacturing practice

1. The manufacture of cosmetic products shall comply with good manufacturing practice with a view to ensuring the objectives of Article 1.

2. Compliance with good manufacturing practice shall be presumed where the manufacture is in accordance with the relevant harmonised standards, the references of which have been published in the Official Journal of the European Union.

Article 9

Free movement

Member States shall not, for reasons related to the requirements laid down in this Regulation, refuse, prohibit or restrict the making available on the market of cosmetic products which comply with the requirements of this Regulation.







CHAPTER III

SAFETY ASSESSMENT, PRODUCT INFORMATION FILE, NOTIFICATION

Article 10

Safety assessment

1. In order to demonstrate that a cosmetic product complies with Article 3, the responsible person shall, prior to placing a cosmetic product on the market, ensure that the cosmetic product has undergone a safety assessment on the basis of the relevant information and that a cosmetic product safety report is set up in accordance with Annex I.

The responsible person shall ensure that:

(a) the intended use of the cosmetic product and the anticipated systemic exposure to individual ingredients in a final formulation are taken into account in the safety assessment;

(b) an appropriate weight-of-evidence approach is used in the safety assessment for reviewing data from all existing sources;

(c) the cosmetic product safety report is kept up to date in view of additional relevant information generated subsequent to placing the product on the market.

The first subparagraph shall also apply to cosmetic products that have been notified under Directive 76/768/EEC.

The Commission, in close cooperation with all stakeholders, shall adopt appropriate guidelines to enable undertakings, in particular small and medium-sized enterprises, to comply with the requirements laid down in Annex I. Those guidelines shall be adopted in accordance with the regulatory procedure referred to in Article 32(2).

2. The cosmetic product safety assessment, as set out in Part B of Annex I shall be carried out by a person in possession of a diploma or other evidence of formal qualifications awarded on completion of a university course of theoretical and practical study in pharmacy, toxicology, medicine or a similar discipline, or a course recognised as equivalent by a Member State.

3. Non-clinical safety studies referred to in the safety assessment according to paragraph 1 and carried out after 30 June 1988 for the purpose of assessing the safety of a cosmetic product shall comply with Community legislation on the principles of good laboratory practice, as applicable at the time of performance of the study, or with other international standards recognised as being equivalent by the Commission or the ECHA.

Article 11

Product information file

1. When a cosmetic product is placed on the market, the responsible person shall keep a product information file for it. The product information file shall be kept for a period of ten years following the date on which the last batch of the cosmetic product was placed on the market.

2. The product information file shall contain the following information and data which shall be updated as necessary:

(a) a description of the cosmetic product which enables the product information file to be clearly attributed to the cosmetic product;

(b) the cosmetic product safety report referred to in Article 10(1);

(c) a description of the method of manufacturing and a statement on compliance with good manufacturing practice referred to in Article 8;

(d) where justified by the nature or the effect of the cosmetic product, proof of the effect claimed for the cosmetic product;

(e) data on any animal testing performed by the manufacturer, his agents or suppliers, relating to the development or safety assessment of the cosmetic product or its ingredients, including any animal testing performed to meet the legislative or regulatory requirements of third countries.

3. The responsible person shall make the product information file readily accessible in electronic or other format at his address indicated on the label to the competent authority of the Member State in which the file is kept.

The information contained in the product information file shall be available in a language which can be easily understood by the competent authorities of the Member State.

4. The requirements provided in paragraphs 1 to 3 of this Article shall also apply to cosmetic products that have been notified under Directive 76/768/EEC.

Article 12

Sampling and analysis

1. Sampling and analysis of cosmetic products shall be performed in a reliable and reproducible manner.

2. In the absence of any applicable Community legislation, reliability and reproducibility shall be presumed if the method used is in accordance with the relevant harmonised standards, the references of which have been published in the Official Journal of the European Union.

Article 13

Notification

1. Prior to placing the cosmetic product on the market the responsible person shall submit, by electronic means, the following information to the Commission:

(a) the category of cosmetic product and its name or names, enabling its specific identification;

(b) the name and address of the responsible person where the product information file is made readily accessible;

(c) the country of origin in the case of import;

(d) the Member State in which the cosmetic product is to be placed on the market;

(e) the contact details of a physical person to contact in the case of necessity;

(f) the presence of substances in the form of nanomaterials and: (i) their identification including the chemical name (IUPAC) and other descriptors as specified in point 2 of the Preamble to Annexes II to VI to this Regulation; (ii) the reasonably foreseeable exposure conditions;

(g) the name and the Chemicals Abstracts Service (CAS) or EC number of substances classified as carcinogenic, mutagenic or toxic for reproduction (CMR), of category 1A or 1B, under Part 3 of Annex VI to Regulation (EC) No 1272/2008;

(h) the frame formulation allowing for prompt and appropriate medical treatment in the event of difficulties.

The first subparagraph shall also apply to cosmetic products notified under Directive 76/768/EEC.

2. When the cosmetic product is placed on the market, the responsible person shall notify to the Commission the original labelling, and, where reasonably legible, a photograph of the corresponding packaging.

3. As from 11 July 2013, a distributor who makes available in a Member State a cosmetic product already placed on the market in another Member State and translates, on his own initiative, any element of the labelling of that product in order to comply with national law, shall submit, by electronic means, the following information to the Commission:

(a) the category of cosmetic product, its name in the Member State of dispatch and its name in the Member State in which it is made available, enabling its specific identification;

(b) the Member State in which the cosmetic product is made available;

(c) his name and address;

(d) the name and address of the responsible person where the product information file is made readily accessible.

4. Where a cosmetic product has been placed on the market before 11 July 2013 but is no longer placed on the market as from that date, and a distributor introduces that product in a Member State after that date, that distributor shall communicate the following to the responsible person:

(a) the category of cosmetic product, its name in the Member State of dispatch and its name in the Member State in which it is made available, enabling its specific identification;

(b) the Member State in which the cosmetic product is made available;

(c) his name and address.

On the basis of that communication, the responsible person shall submit to the Commission, by electronic means, the information referred to in paragraph 1 of this Article, where notifications according to Article 7(3) and Article 7a (4) of Directive 76/768/EEC have not been carried out in the Member State in which the cosmetic product is made available.

5. The Commission shall, without delay, make the information referred to in points (a) to (g) of paragraph 1, and in paragraphs 2 and 3 available electronically to all competent authorities.

That information may be used by competent authorities only for the purposes of market surveillance, market analysis, evaluation and consumer information in the context of Articles 25, 26 and 27.

6. The Commission shall, without delay, make the information referred to in paragraphs 1, 2 and 3 available electronically to poison centres or similar bodies, where such centres or bodies have been established by Member States.

That information may be used by those bodies only for the purposes of medical treatment.

7. Where any of the information set out in paragraphs 1, 3 and 4 changes, the responsible person or the distributor shall provide an update without delay.

8. The Commission may, taking into account technical and scientific progress and specific needs related to market surveillance, amend paragraphs 1 to 7 by adding requirements.

Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).







CHAPTER IV

RESTRICTIONS FOR CERTAIN SUBSTANCES

Article 14

Restrictions for substances listed in the Annexes

1. Without prejudice to Article 3, cosmetic products shall not contain any of the following:

(a) prohibited substances — prohibited substances listed in Annex II;

(b) restricted substances — restricted substances which are not used in accordance with the restrictions laid down in Annex III;

(c) colorants (i) colorants other than those listed in Annex IV and colorants which are listed there but not used in accordance with the conditions laid down in that Annex, except for hair colouring products referred to in paragraph 2; (ii) without prejudice to points (b), (d)(i) and (e)(i), substances which are listed in Annex IV but which are not intended to be used as colorants, and which are not used in accordance with the conditions laid down in that Annex;

(d) preservatives (i) preservatives other than those listed in Annex V and preservatives which are listed there but not used in accordance with the conditions laid down in that Annex; (ii) without prejudice to points (b), (c)(i) and (e)(i), substances listed in Annex V but which are not intended to be used as preservatives, and which are not used in accordance with the conditions laid down in that Annex;

(e) UV-filters (i) UV-filters other than those listed in Annex VI and UV-filters which are listed there but not used in accordance with the conditions laid down in that Annex; (ii) without prejudice to points (b), (c)(i) and (d)(i), substances listed in Annex VI but which are not intended to be used as UV-filters and which are not used in accordance with the conditions laid down in that Annex.

2. Subject to a decision of the Commission to extend the scope of Annex IV to hair colouring products, such products shall not contain colorants intended to colour the hair, other than those listed in Annex IV and colorants intended to colour the hair which are listed there but not used in accordance with the conditions laid down in that Annex.

The decision of the Commission referred to in the first subparagraph, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

Article 15

Substances classified as CMR substances

1. The use in cosmetic products of substances classified as CMR substances, of category 2, under Part 3 of Annex VI to Regulation (EC) No 1272/2008 shall be prohibited. However, a substance classified in category 2 may be used in cosmetic products where the substance has been evaluated by the SCCS and found safe for use in cosmetic products. To these ends the Commission shall adopt the necessary measures in accordance with the regulatory procedure with scrutiny referred to in Article 32(3) of this Regulation.

2. The use in cosmetic products of substances classified as CMR substances, of category 1A or 1B under Part 3 of Annex VI to Regulation (EC) No 1272/2008 shall be prohibited.

However, such substances may be used in cosmetic products by way of exception where, subsequent to their classification as CMR substances of category 1A or 1B under Part 3 of Annex VI to Regulation (EC) No 1272/2008, all of the following conditions are fulfilled:

(a) they comply with the food safety requirements as defined in Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety ( 2 );

(b) there are no suitable alternative substances available, as documented in an analysis of alternatives;

(c) the application is made for a particular use of the product category with a known exposure; and

(d) they have been evaluated and found safe by the SCCS for use in cosmetic products, in particular in view of exposure to these products and taking into consideration the overall exposure from other sources, taking particular account of vulnerable population groups.

Specific labelling in order to avoid misuse of the cosmetic product shall be provided in accordance with Article 3 of this Regulation, taking into account possible risks linked to the presence of hazardous substances and the routes of exposure.

In order to implement this paragraph, the Commission shall amend the Annexes to this Regulation in accordance with the regulatory procedure with scrutiny referred to in Article 32(3) of this Regulation within 15 months of the inclusion of the substances concerned in Part 3 of Annex VI to Regulation (EC) No 1272/2008.

On imperative grounds of urgency, the Commission may use the urgency procedure referred to in Article 32(4) of this Regulation.

The Commission shall mandate the SCCS to re-evaluate those substances as soon as safety concerns arise, and at the latest five years after their inclusion in Annexes III to VI to this Regulation, and at least every subsequent five years.

3. By 11 January 2012, the Commission shall ensure that appropriate guidance is developed with the aim of enabling a harmonised approach to the development and use of overall exposure estimates in assessing the safe use of CMR substances. This guidance shall be developed in consultation with the SCCS, the ECHA, the EFSA and other relevant stakeholders, drawing, as appropriate, on relevant best practice.

4. When Community or internationally agreed criteria for identifying substances with endocrine-disrupting properties are available, or at the latest on 11 January 2015, the Commission shall review this Regulation with regard to substances with endocrine-disrupting properties.

Article 16

Nanomaterials

1. For every cosmetic product that contains nanomaterials, a high level of protection of human health shall be ensured.

2. The provisions of this Article do not apply to nanomaterials used as colorants, UV-filters or preservatives regulated under Article 14, unless expressly specified.

3. In addition to the notification under Article 13, cosmetic products containing nanomaterials shall be notified to the Commission by the responsible person by electronic means six months prior to being placed on the market, except where they have already been placed on the market by the same responsible person before 11 January 2013.

In the latter case, cosmetic products containing nanomaterials placed on the market shall be notified to the Commission by the responsible person between 11 January 2013 and 11 July 2013 by electronic means, in addition to the notification in Article 13.

The first and the second subparagraphs shall not apply to cosmetic products containing nanomaterials that are in conformity with the requirements set out in Annex III.

The information notified to the Commission shall contain at least the following:

(a) the identification of the nanomaterial including its chemical name (IUPAC) and other descriptors as specified in point 2 of the Preamble to Annexes II to VI;

(b) the specification of the nanomaterial including size of particles, physical and chemical properties;

(c) an estimate of the quantity of nanomaterial contained in cosmetic products intended to be placed on the market per year;

(d) the toxicological profile of the nanomaterial;

(e) the safety data of the nanomaterial relating to the category of cosmetic product, as used in such products;

(f) the reasonably foreseeable exposure conditions.

The responsible person may designate another legal or natural person by written mandate for the notification of nanomaterials and shall inform the Commission thereof.

The Commission shall provide a reference number for the submission of the toxicological profile, which may substitute the information to be notified under point (d).

4. In the event that the Commission has concerns regarding the safety of a nanomaterial, the Commission shall, without delay, request the SCCS to give its opinion on the safety of such nanomaterial for use in the relevant categories of cosmetic products and on the reasonably foreseeable exposure conditions. The Commission shall make this information public. The SCCS shall deliver its opinion within six months of the Commission's request. Where the SCCS finds that any necessary data is lacking, the Commission shall request the responsible person to provide such data within an explicitly stated reasonable time, which shall not be extended. The SCCS shall deliver its final opinion within six months of submission of additional data. The opinion of the SCCS shall be made publicly available.

5. The Commission may, at any time, invoke the procedure in paragraph 4 where it has any safety concerns, for example due to new information supplied by a third party.

6. Taking into account the opinion of the SCCS, and where there is a potential risk to human health, including when there is insufficient data, the Commission may amend Annexes II and III.

7. The Commission may, taking into account technical and scientific progress, amend paragraph 3 by adding requirements.

8. The measures, referred to in paragraphs 6 and 7, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

9. On imperative grounds of urgency the Commission may use the procedure referred to in Article 32(4).

10. The following information shall be made available by the Commission:

(a) By 11 January 2014, the Commission shall make available a catalogue of all nanomaterials used in cosmetic products placed on the market, including those used as colorants, UV-filters and preservatives in a separate section, indicating the categories of cosmetic products and the reasonably foreseeable exposure conditions. This catalogue shall be regularly updated thereafter and be made publicly available.

(b) The Commission shall submit to the European Parliament and the Council an annual status report, which will give information on developments in the use of nanomaterials in cosmetic products within the Community, including those used as colorants, UV-filters and preservatives in a separate section. The first report shall be presented by 11 July 2014 The report update shall summarise, in particular, the new nanomaterials in new categories of cosmetic products, the number of notifications, the progress made in developing nano-specific assessment methods and safety assessment guides, and information on international cooperation programmes.

11. The Commission shall regularly review the provisions of this Regulation concerning nanomaterials in the light of scientific progress and shall, where necessary, propose suitable amendments to those provisions.

The first review shall be undertaken by 11 July 2018.

Article 17

Traces of prohibited substances

The non-intended presence of a small quantity of a prohibited substance, stemming from impurities of natural or synthetic ingredients, the manufacturing process, storage, migration from packaging, which is technically unavoidable in good manufacturing practice, shall be permitted provided that such presence is in conformity with Article 3.







CHAPTER V

ANIMAL TESTING

Article 18

Animal testing

1. Without prejudice to the general obligations deriving from Article 3, the following shall be prohibited:

(a) the placing on the market of cosmetic products where the final formulation, in order to meet the requirements of this Regulation, has been the subject of animal testing using a method other than an alternative method after such alternative method has been validated and adopted at Community level with due regard to the development of validation within the OECD;

(b) the placing on the market of cosmetic products containing ingredients or combinations of ingredients which, in order to meet the requirements of this Regulation, have been the subject of animal testing using a method other than an alternative method after such alternative method has been validated and adopted at Community level with due regard to the development of validation within the OECD;

(c) the performance within the Community of animal testing of finished cosmetic products in order to meet the requirements of this Regulation;

(d) the performance within the Community of animal testing of ingredients or combinations of ingredients in order to meet the requirements of this Regulation, after the date on which such tests are required to be replaced by one or more validated alternative methods listed in Commission Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) ( 3 ) or in Annex VIII to this Regulation.

2. The Commission, after consulting the SCCS and the European Centre for the Validation of Alternative Methods (ECVAM) and with due regard to the development of validation within the OECD, has established timetables for the implementation of the provisions under points (a), (b) and (d) of paragraph 1, including deadlines for the phasing-out of the various tests. The timetables were made available to the public on 1 October 2004 and sent to the European Parliament and the Council. The period for implementation was limited to 11 March 2009 in relation to points (a), (b) and (d) of paragraph 1.

In relation to the tests concerning repeated-dose toxicity, reproductive toxicity and toxicokinetics, for which there are no alternatives yet under consideration, the period for implementation of paragraph 1(a) and (b) shall be limited to 11 March 2013.

The Commission shall study possible technical difficulties in complying with the ban in relation to tests, in particular those concerning repeated-dose toxicity, reproductive toxicity and toxicokinetics, for which there are no alternatives yet under consideration. Information about the provisional and final results of these studies forms part of the yearly reports presented pursuant to Article 35.

On the basis of these annual reports, the timetables established as referred to in the first subparagraph, could be adapted up to 11 March 2009 in relation to the first subparagraph and may be adapted up to 11 March 2013 in relation to the second subparagraph and after consultation of the entities referred to in the first subparagraph.

The Commission shall study progress and compliance with the deadlines as well as possible technical difficulties in complying with the ban. Information about the provisional and final results of the Commission studies forms part of the yearly reports presented pursuant to Article 35. If these studies conclude, at the latest two years prior to the end of the maximum period referred to in the second subparagraph, that for technical reasons one or more tests referred to in that subparagraph will not be developed and validated before the expiry of the period referred to therein it shall inform the European Parliament and the Council and shall put forward a legislative proposal in accordance with Article 251 of the Treaty.

In exceptional circumstances, where serious concerns arise as regards the safety of an existing cosmetic ingredient, a Member State may request the Commission to grant a derogation from paragraph 1. The request shall contain an evaluation of the situation and indicate the measures necessary. On this basis, the Commission may, after consulting the SCCS and by means of a reasoned decision, authorise the derogation. That authorisation shall lay down the conditions associated with this derogation in terms of specific objectives, duration and reporting of the results.

A derogation shall be granted only where:

(a) the ingredient is in wide use and cannot be replaced by another ingredient capable of performing a similar function;

(b) the specific human health problem is substantiated and the need to conduct animal tests is justified and is supported by a detailed research protocol proposed as the basis for the evaluation.

The decision on the authorisation, the conditions associated with it and the final result achieved shall be part of the annual report presented by the Commission in accordance with Article 35.

The measures referred to in the sixth subparagraph, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

3. For the purposes of this Article and Article 20:

(a) ‘finished cosmetic product’ means the cosmetic product in its final formulation, as placed on the market and made available to the end user, or its prototype;

(b) ‘prototype’ means a first model or design that has not been produced in batches, and from which the finished cosmetic product is copied or finally developed.







CHAPTER VI

CONSUMER INFORMATION

Article 19

Labelling

1. Without prejudice to other provisions in this Article, cosmetic products shall be made available on the market only where the container and packaging of cosmetic products bear the following information in indelible, easily legible and visible lettering:

(a) the name or registered name and the address of the responsible person. Such information may be abbreviated in so far as the abbreviation makes it possible to identify that person and his address. If several addresses are indicated, the one where the responsible person makes readily available the product information file shall be highlighted. The country of origin shall be specified for imported cosmetic products;

(b) the nominal content at the time of packaging, given by weight or by volume, except in the case of packaging containing less than five grams or five millilitres, free samples and single-application packs; for pre-packages normally sold as a number of items, for which details of weight or volume are not significant, the content need not be given provided the number of items appears on the packaging. This information need not be given if the number of items is easy to see from the outside or if the product is normally only sold individually;

(c) the date until which the cosmetic product, stored under appropriate conditions, will continue to fulfil its initial function and, in particular, will remain in conformity with Article 3 (‘date of minimum durability’). The date itself or details of where it appears on the packaging shall be preceded by the symbol shown in point 3 of Annex VII or the words: ‘best used before the end of’. The date of minimum durability shall be clearly expressed and shall consist of either the month and year or the day, month and year, in that order. If necessary, this information shall be supplemented by an indication of the conditions which must be satisfied to guarantee the stated durability. Indication of the date of minimum durability shall not be mandatory for cosmetic products with a minimum durability of more than 30 months. For such products, there shall be an indication of the period of time after opening for which the product is safe and can be used without any harm to the consumer. This information shall be indicated, except where the concept of durability after opening is not relevant, by the symbol shown in point 2 of Annex VII followed by the period (in months and/or years);

(d) particular precautions to be observed in use, and at least those listed in Annexes III to VI and any special precautionary information on cosmetic products for professional use;

(e) the batch number of manufacture or the reference for identifying the cosmetic product. Where this is impossible for practical reasons because the cosmetic products are too small, such information need appear only on the packaging;

(f) the function of the cosmetic product, unless it is clear from its presentation;

(g) a list of ingredients. This information may be indicated on the packaging alone. The list shall be preceded by the term ‘ingredients’. For the purpose of this Article, an ingredient means any substance or mixture intentionally used in the cosmetic product during the process of manufacturing. The following shall not, however, be regarded as ingredients: (i) impurities in the raw materials used; (ii) subsidiary technical materials used in the mixture but not present in the final product. Perfume and aromatic compositions and their raw materials shall be referred to by the terms ‘parfum’ or ‘aroma’. Moreover, the presence of substances, the mention of which is required under the column ‘Other’ in Annex III, shall be indicated in the list of ingredients in addition to the terms parfum or aroma. The list of ingredients shall be established in descending order of weight of the ingredients at the time they are added to the cosmetic product. Ingredients in concentrations of less than 1 % may be listed in any order after those in concentrations of more than 1 %. All ingredients present in the form of nanomaterials shall be clearly indicated in the list of ingredients. The names of such ingredients shall be followed by the word ‘nano’ in brackets. Colorants other than colorants intended to colour the hair may be listed in any order after the other cosmetic ingredients. For decorative cosmetic products marketed in several colour shades, all colorants other than colorants intended to colour the hair used in the range may be listed, provided that the words ‘may contain’ or the symbol ‘+/-’ are added. The CI (Colour Index) nomenclature shall be used, where applicable.

2. Where it is impossible for practical reasons to label the information mentioned in points (d) and (g) of paragraph 1 as provided, the following applies:

— the information shall be mentioned on an enclosed or attached leaflet, label, tape, tag or card;

— unless impracticable, this information shall be referred to by abbreviated information or the symbol given in point 1 of Annex VII, which must appear on the container or packaging for the information referred in point (d) of paragraph 1 and on packaging for the information referred in point (g) of paragraph 1.

3. In the case of soap, bath balls and other small products where it is impossible for practical reasons for the information referred to in point (g) of paragraph 1 to appear on a label, tag, tape or card or in an enclosed leaflet, this information shall appear on a notice in immediate proximity to the container in which the cosmetic product is exposed for sale.

4. For cosmetic products that are not pre-packaged, are packaged at the point of sale at the purchaser's request, or are pre-packaged for immediate sale, Member States shall adopt detailed rules for indication of the information referred to in paragraph 1.

5. The language of the information mentioned in points (b), (c), (d) and (f) of paragraph 1 and in paragraphs (2), (3) and (4) shall be determined by the law of the Member States in which the product is made available to the end user.

6. The information mentioned in point (g) of paragraph 1 shall be expressed by using the common ingredient name set out in the glossary provided for in Article 33. In the absence of a common ingredient name, a term as contained in a generally accepted nomenclature shall be used.

Article 20

Product claims

1. In the labelling, making available on the market and advertising of cosmetic products, text, names, trade marks, pictures and figurative or other signs shall not be used to imply that these products have characteristics or functions which they do not have.

2. The Commission shall, in cooperation with Member States, establish an action plan regarding claims used and fix priorities for determining common criteria justifying the use of a claim.

After consulting the SCCS or other relevant authorities, the Commission shall adopt a list of common criteria for claims which may be used in respect of cosmetic products, in accordance with the regulatory procedure with scrutiny referred to in Article 32(3) of this Regulation, taking into account the provisions of Directive 2005/29/EC.

By 11 July 2016, the Commission shall submit to the European Parliament and the Council a report regarding the use of claims on the basis of the common criteria adopted under the second subparagraph. If the report concludes that claims used in respect of cosmetic products are not in conformity with the common criteria, the Commission shall take appropriate measures to ensure compliance in cooperation with the Member States.

3. The responsible person may refer, on the product packaging or in any document, notice, label, ring or collar accompanying or referring to the cosmetic product, to the fact that no animal tests have been carried out only if the manufacturer and his suppliers have not carried out or commissioned any animal tests on the finished cosmetic product, or its prototype, or any of the ingredients contained in it, or used any ingredients that have been tested on animals by others for the purpose of developing new cosmetic products.

Article 21

Access to information for the public

Without prejudice to the protection, in particular, of commercial secrecy and of intellectual property rights, the responsible person shall ensure that the qualitative and quantitative composition of the cosmetic product and, in the case of perfume and aromatic compositions, the name and code number of the composition and the identity of the supplier, as well as existing data on undesirable effects and serious undesirable effects resulting from use of the cosmetic product are made easily accessible to the public by any appropriate means.

The quantitative information regarding composition of the cosmetic product required to be made publicly accessible shall be limited to hazardous substances in accordance with Article 3 of Regulation (EC) No 1272/2008.







CHAPTER VII

MARKET SURVEILLANCE

Article 22

In-market control

Member States shall monitor compliance with this Regulation via in-market controls of the cosmetic products made available on the market. They shall perform appropriate checks of cosmetic products and checks on the economic operators on an adequate scale, through the product information file and, where appropriate, physical and laboratory checks on the basis of adequate samples.

Member States shall also monitor compliance with the principles of good manufacturing practices.

Member States shall entrust to market surveillance authorities the necessary powers, resources and knowledge in order for those authorities to properly perform their tasks.

Member States shall periodically review and assess the functioning of their surveillance activities. Such reviews and assessments shall be carried out at least every four years and the results thereof shall be communicated to the other Member States and the Commission and be made available to the public, by way of electronic communication and, where appropriate, by other means.

Article 23

Communication of serious undesirable effects

1. In the event of serious undesirable effects, the responsible person and distributors shall without delay notify the following to the competent authority of the Member State where the serious undesirable effect occurred:

(a) all serious undesirable effects which are known to him or which may reasonably be expected to be known to him;

(b) the name of the cosmetic product concerned, enabling its specific identification;

(c) the corrective measures taken by him, if any.

2. Where the responsible person reports serious undesirable effects to the competent authority of the Member State where the effect occurred, that competent authority shall immediately transmit the information referred to in paragraph 1 to the competent authorities of the other Member States.

3. Where distributors report serious undesirable effects to the competent authority of the Member State where the effect occurred, that competent authority shall immediately transmit the information referred to in paragraph 1 to the competent authorities of the other Member States and to the responsible person.

4. Where end users or health professionals report serious undesirable effects to the competent authority of the Member State where the effect occurred, that competent authority shall immediately transmit the information on the cosmetic product concerned to the competent authorities of the other Member States and to the responsible person.

5. Competent authorities may use the information referred to in this Article for the purposes of in-market surveillance, market analysis, evaluation and consumer information in the context of Articles 25, 26 and 27.

Article 24

Information on substances

In the event of serious doubt regarding the safety of any substance contained in cosmetic products, the competent authority of a Member State in which a product containing such a substance is made available on the market may by reasoned request require the responsible person to submit a list of all cosmetic products for which he is responsible and which contain this substance. The list shall indicate the concentration of this substance in the cosmetic products.

Competent authorities may use the information referred to in this Article for the purposes of in-market surveillance, market analysis, evaluation and consumer information in the context of Articles 25, 26 and 27.







CHAPTER VIII

NON-COMPLIANCE, SAFEGUARD CLAUSE

Article 25

Non-compliance by the responsible person

1. Without prejudice to paragraph 4, competent authorities shall require the responsible person to take all appropriate measures, including corrective actions bringing the cosmetic product into conformity, the withdrawal of the product from the market or its recall, within an expressly mentioned time limit, commensurate with the nature of the risk, where there is non-compliance with any of the following:

(a) the good manufacturing practice referred to in Article 8;

(b) the safety assessment referred to in Article 10;

(c) the requirements for the product information file referred to in Article 11;

(d) the provisions on sampling and analysis referred to in Article 12;

(e) the notification requirements referred to in Articles 13 and 16;

(f) the restrictions for substances referred to in Articles 14, 15 and 17;

(g) the animal testing requirements referred to in Article 18;

(h) the labelling requirements referred to in Article 19(1), (2), (5) and (6);

(i) the requirements related to product claims set out in Article 20;

(j) the access to information for the public referred to in Article 21;

(k) the communication of serious undesirable effects referred to in Article 23;

(l) the information requirements on substances referred to in Article 24.

2. Where applicable, a competent authority shall inform the competent authority of the Member State in which the responsible person is established of the measures which it has required the responsible person to take.

3. The responsible person shall ensure that the measures referred to in paragraph 1 are taken in respect of all the products concerned which are made available on the market throughout the Community.

4. In the case of serious risks to human health, where the competent authority considers that the non-compliance is not limited to the territory of the Member State in which the cosmetic product is made available on the market, it shall inform the Commission and the competent authorities of the other Member States of the measures which it has required the responsible person to take.

5. The competent authority shall take all appropriate measures to prohibit or restrict the making available on the market of the cosmetic product or to withdraw the product from the market or to recall it in the following cases:

(a) where an immediate action is necessary in the event of serious risk to human health; or

(b) where the responsible person does not take all appropriate measures within the time limit referred to in paragraph 1.

In the event of serious risks to human health, that competent authority shall inform the Commission and the competent authorities of the other Member States, without delay, of the measures taken.

6. In the absence of a serious risk to human health, in the event that the responsible person does not take all appropriate measures, the competent authority shall without delay inform the competent authority of the Member State in which the responsible person is established of the measures taken.

7. For the purposes of paragraphs 4 and 5 of this Article, the information exchange system provided for in Article 12(1) of Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product safety ( 4 ) shall be used.

Article 12(2), (3) and (4) of Directive 2001/95/EC and Article 23 of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products ( 5 ) shall also apply.

Article 26

Non-compliance by distributors

Competent authorities shall require distributors to take all appropriate measures, including corrective actions bringing the cosmetic product into conformity, the withdrawal of the product from the market or its recall, within a given reasonable time limit, commensurate with the nature of the risk, where there is non-compliance with obligations laid down in Article 6.

Article 27

Safeguard clause

1. In the case of products meeting the requirements listed in Article 25(1), where a competent authority ascertains, or has reasonable grounds for concern, that a cosmetic product or products made available on the market present or could present a serious risk to human health, it shall take all appropriate provisional measures in order to ensure that the product or products concerned are withdrawn, recalled or their availability is otherwise restricted.

2. The competent authority shall immediately communicate to the Commission and the competent authorities of the other Member States the measures taken and any supporting data.

For the purposes of the first subparagraph, the information exchange system provided for in Article 12(1) of Directive 2001/95/EC shall be used.

Article 12(2), (3) and (4) of Directive 2001/95/EC shall apply.

3. The Commission shall determine, as soon as possible, whether the provisional measures referred to in paragraph 1 are justified or not. For that purpose it shall, whenever possible, consult the interested parties, the Member States and the SCCS.

4. Where the provisional measures are justified, Article 31(1) shall apply.

5. Where the provisional measures are not justified the Commission shall inform the Member States thereof and the competent authority concerned shall repeal the provisional measures in question.

Article 28

Good administrative practices

1. Any decision taken pursuant to Articles 25 and 27 shall state the exact grounds on which it is based. It shall be notified by the competent authority without delay to the responsible person, who shall at the same time be informed of the remedies available to him under the law of the Member State concerned and of the time limits to which remedies are subject.

2. Except in the case where immediate action is necessary for reasons of serious risk to human health, the responsible person shall have the opportunity to put forward his viewpoint before any decision is taken.

3. Where applicable, the provisions mentioned in paragraphs 1 and 2 shall apply with regard to the distributor for any decisions taken pursuant to Articles 26 and 27.







CHAPTER IX

ADMINISTRATIVE COOPERATION

Article 29

Cooperation between competent authorities

1. The competent authorities of the Member States shall cooperate with each other and with the Commission to ensure the proper application and due enforcement of this Regulation and shall transmit to each other all information necessary with a view to applying this Regulation uniformly.

2. The Commission shall provide for the organisation of an exchange of experience between the competent authorities in order to coordinate the uniform application of this Regulation.

3. Cooperation may be part of initiatives developed at international level.

Article 30

Cooperation regarding verification of product information files

The competent authority of any Member State where the cosmetic product is made available may request the competent authority of the Member State where the product information file is made readily accessible to verify whether the product information file satisfies the requirements referred to in Article 11(2) and whether the information set out therein provides evidence of the safety of the cosmetic product.

The requesting competent authority shall provide a motivation for the request.

Upon that request, the competent authority requested shall, without undue delay and taking into account the degree of urgency, carry out the verification and shall inform the requesting competent authority of its findings.







CHAPTER X

IMPLEMENTING MEASURES, FINAL PROVISIONS

Article 31

Amendment of the Annexes

1. Where there is a potential risk to human health, arising from the use of substances in cosmetic products, which needs to be addressed on a Community-wide basis, the Commission may, after consulting the SCCS, amend Annexes II to VI accordingly.

Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

On imperative grounds of urgency, the Commission may use the urgency procedure referred to in Article 32(4).

2. The Commission may, after consulting the SCCS, amend Annexes III to VI and VIII for the purposes of adapting them to technical and scientific progress.

Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

3. Where it appears necessary, in order to ensure the safety of cosmetic products placed on the market, the Commission may, after consulting the SCCS, amend Annex I.

Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).

Article 32

Committee procedure

1. The Commission shall be assisted by the Standing Committee on Cosmetic Products.

2. Where reference is made to this paragraph, Articles 5 and 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.

The period laid down in Article 5(6) of Decision 1999/468/EC shall be set at three months.

3. Where reference is made to this paragraph, Article 5a(1) to (4) and Article 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.

4. Where reference is made to this paragraph, Article 5a(1), (2), (4) and (6) and Article 7 of Decision 1999/468/EC shall apply having regard to the provisions of Article 8 thereof.

Article 33

Glossary of common ingredient names

The Commission shall compile and update a glossary of common ingredient names. To this end, the Commission shall take account of internationally recognised nomenclatures including the International Nomenclature of Cosmetic Ingredients (INCI). That glossary shall not constitute a list of the substances authorised for use in cosmetic products.

The common ingredient name shall be applied for the purpose of labelling cosmetic products placed on the market at the latest twelve months after publication of the glossary in the Official Journal of the European Union.

Article 34

Competent authorities, poison control centres or assimilated entities

1. Member States shall designate their national competent authorities.

2. Member States shall communicate the details of authorities referred to in paragraph 1 and of the poison centres and similar bodies referred to in Article 13(6) to the Commission. They shall communicate an update of these details as necessary.

3. The Commission shall compile and update a list of the authorities and bodies referred to in paragraph 2 and make it available to the public.

Article 35

Annual report on animal testing

Every year the Commission shall present a report to the European Parliament and the Council on:

(1) progress made in the development, validation and legal acceptance of alternative methods. The report shall contain precise data on the number and type of experiments relating to cosmetic products carried out on animals. The Member States shall be obliged to collect that information in addition to collecting statistics as laid down by Directive 86/609/EEC. The Commission shall in particular ensure the development, validation and legal acceptance of alternative test methods which do not use live animals;

(2) progress made by the Commission in its efforts to obtain acceptance by the OECD of alternative methods validated at Community level and recognition by third countries of the results of the safety tests carried out in the Community using alternative methods, in particular within the framework of cooperation agreements between the Community and these countries;

(3) the manner in which the specific needs of small and medium-sized enterprises have been taken into account.

Article 36

Formal objection against harmonised standards

1. When a Member State or the Commission considers that a harmonised standard does not entirely satisfy the requirements set out in the relevant provisions of this Regulation, the Commission or the Member State concerned shall bring the matter before the Committee set up by Article 5 of Directive 98/34/EC, giving its arguments. The Committee shall deliver its opinion without delay.

2. In the light of the Committee's opinion, the Commission shall decide to publish, not to publish, to publish with restriction, to maintain, to maintain with restriction or to withdraw the references to the harmonised standard concerned in the Official Journal of the European Union.

3. The Commission shall inform the Member States and the European standardisation body concerned. It shall, if necessary, request the revision of the harmonised standards concerned.

Article 37

Penalties

Member States shall lay down the provisions on penalties applicable for infringement of the provisions of this Regulation and shall take all measures necessary to ensure that they are implemented. The penalties provided for must be effective, proportionate and dissuasive. The Member States shall notify those provisions to the Commission by 11 July 2013 and shall notify it without delay of any subsequent amendment affecting them.

Article 38

Repeal

Directive 76/768/EEC is repealed with effect from 11 July 2013, with the exception of Article 4b which is repealed with effect from 1 December 2010.

References to the repealed Directive shall be understood as references to this Regulation.

This Regulation shall be without prejudice to the obligations of the Member States relating to the time-limits for transposition into national law of the Directives set out in Part B of Annex IX.

However, the competent authorities shall continue to keep available the information received pursuant to Article 7(3) and Article 7a(4) of Directive 76/768/EEC and responsible persons shall continue to keep readily accessible the information collected pursuant to Article 7a of that Directive until 11 July 2020.

Article 39

Transitional provisions

By way of derogation from Directive 76/768/EEC, cosmetic products which comply with this Regulation may be placed on the market before 11 July 2013.

As from 11 January 2012, by way of derogation from Directive 76/768/EEC, notification carried out in accordance with Article 13 of this Regulation shall be considered to comply with Article 7(3) and Article 7a(4) of that Directive.

Article 40

Entry into force and date of application

1. This Regulation shall enter into force on the [twentieth day after its publication in the Official Journal of the European Union

2. It shall apply from 11 July 2013, with the exception of:

— Article 15(1) and (2) which shall apply from 1 December 2010, as well as Articles 14, 31 and 32 to the extent that they are necessary to apply Article 15(1) and (2); and

— Article 16(3) second subparagraph, which shall apply from 11 January 2013.

This Regulation shall be binding in its entirety and directly applicable in all Member States.









ANNEX I

COSMETIC PRODUCT SAFETY REPORT

The cosmetic product safety report shall, as a minimum, contain the following:

PART A – Cosmetic product safety information

1. Quantitative and qualitative composition of the cosmetic product

The qualitative and quantitative composition of the cosmetic product, including chemical identity of the substances (incl. chemical name, INCI, CAS, EINECS/ELINCS, where possible) and their intended function. In the case of perfume and aromatic compositions, description of the name and code number of the composition and the identity of the supplier.

2. Physical/chemical characteristics and stability of the cosmetic product

The physical and chemical characteristics of the substances or mixtures, as well as the cosmetic product.

The stability of the cosmetics product under reasonably foreseeable storage conditions.

3. Microbiological quality

The microbiological specifications of the substance or mixture and the cosmetic product. Particular attention shall be paid to cosmetics used around the eyes, on mucous membranes in general, on damaged skin, on children under three years of age, on elderly people and persons showing compromised immune responses.

Results of preservation challenge test.

4. Impurities, traces, information about the packaging material

The purity of the substances and mixtures.

In the case of traces of prohibited substances, evidence for their technical unavoidability.

The relevant characteristics of packaging material, in particular purity and stability.

5. Normal and reasonably foreseeable use

The normal and reasonably foreseeable use of the product. The reasoning shall be justified in particular in the light of warnings and other explanations in the product labelling.

6. Exposure to the cosmetic product

Data on the exposure to cosmetic product taking into consideration the findings under Section 5 in relation to

1) The site(s) of application;

2) The surface area(s) of application;

3) The amount of product applied;

4) The duration and frequency of use;

5) The normal and reasonably foreseeable exposure route(s);

6) The targeted (or exposed) population(s). Potential exposure of a specific population shall also be taken into account.

The calculation of the exposure shall also take into consideration the toxicological effects to be considered (e.g. exposure might need to be calculated per unit area of skin or per unit of body weight). The possibility of secondary exposure by routes other than those resulting from direct application should also be considered (e.g. non-intended inhalation of sprays, non-intended ingestion of lip products, etc.).

Particular consideration shall be given to any possible impacts on exposure due to particle sizes.

7. Exposure to the substances

Data on the exposure to the substances contained in the cosmetic product for the relevant toxicological endpoints taking into account the information under Section 6.

8. Toxicological profile of the substances

Without prejudice to Article 18, the toxicological profile of substance contained in the cosmetic product for all relevant toxicological endpoints. A particular focus on local toxicity evaluation (skin and eye irritation), skin sensitisation, and in the case of UV absorption photo-induced toxicity shall be made.

All significant toxicological routes of absorption shall be considered as well as the systemic effects and margin of safety (MoS) based on a no observed adverse effects level (NOAEL) shall be calculated. The absence of these considerations shall be duly justified.

Particular consideration shall be given to any possible impacts on the toxicological profile due to

— particle sizes, including nanomaterials,

— impurities of the substances and raw material used, and

— interaction of substances.

Any read-across shall be duly substantiated and justified.

The source of information shall be clearly identified.

9. Undesirable effects and serious undesirable effects

All available data on the undesirable effects and serious undesirable effects to the cosmetic product or, where relevant, other cosmetic products. This includes statistical data.

10. Information on the cosmetic product

Other relevant information, e.g. existing studies from human volunteers or the duly confirmed and substantiated findings of risk assessments carried out in other relevant areas.

PART B – Cosmetic product safety assessment

1. Assessment conclusion

Statement on the safety of the cosmetic product in relation to Article 3.

2. Labelled warnings and instructions of use

Statement on the need to label any particular warnings and instructions of use in accordance with Article 19(1)(d).

3. Reasoning

Explanation of the scientific reasoning leading to the assessment conclusion set out under Section 1 and the statement set out under Section 2. This explanation shall be based on the descriptions set out under Part A. Where relevant, margins of safety shall be assessed and discussed.

There shall be inter alia a specific assessment for cosmetic products intended for use on children under the age of three and for cosmetic products intended exclusively for use in external intimate hygiene.

Possible interactions of the substances contained in the cosmetic product shall be assessed.

The consideration and non-consideration of the different toxicological profiles shall be duly justified.

Impacts of the stability on the safety of the cosmetic product shall be duly considered.

4. Assessor's credentials and approval of part B

Name and address of the safety assessor.

Proof of qualification of safety assessor.

Date and signature of safety assessor.









Preamble to Annexes II to VI

(1) For the purposes of the Annexes II to VI: (a) ‘Rinse-off product’ means a cosmetic product which is intended to be removed after application on the skin, the hair or the mucous membranes; (b) ‘Leave-on product’ means a cosmetic product which is intended to stay in prolonged contact with the skin, the hair or the mucous membranes; (c) ‘Hair product’ means a cosmetic product which is intended to be applied on the hair of head or face, except eye lashes; (d) ‘Skin product’ means a cosmetic product which is intended to be applied on the skin; (e) ‘Lip product’ means a cosmetic product which is intended to be applied on the lips; (f) ‘Face product’ means a cosmetic product which is intended to be applied on the skin of the face; (g) ‘Nail product’ means a cosmetic product which is intended to be applied on nails; (h) ‘Oral product’ means a cosmetic product which is intended to be applied on teeth or the mucous membranes of the oral cavity; (i) ‘Product applied on mucous membranes’ means a cosmetic product which is intended to be applied on the mucous membranes — of the oral cavity, — on the rim of the eyes, — or of the external genital organs; (j) ‘Eye product’ means a cosmetic product which is intended to be applied in the vicinity of the eyes; (k) ‘Professional use’ means the application and use of cosmetic products by persons in the exercise of their professional activity.

(2) In order to facilitate substance identification, the following descriptors are used: — The Non-proprietary Names (INN) for pharmaceutical products, WHO, Geneva, August 1975; — The Chemical Abstracts Service numbers (CAS); — The EC number which correspond to either the European Inventory of Existing Commercial chemical Substances (EINECS) numbers or the European List of Notified Chemical Substances (ELINCS) numbers or the registration number given under Regulation (EC) No 1907/2006; — The XAN which is the name approved by specific country (X), e.g. USAN which correspond to the United State approved name; — The name in the glossary of common ingredient names referred to in Article 33 of this Regulation.

(3) Substances listed in Annexes III to VI do not cover nanomaterials, except where specifically mentioned.









ANNEX II

LIST OF SUBSTANCES PROHIBITED IN COSMETIC PRODUCTS







Reference number Substance identification Chemical name/INN CAS number EC number a b c d 1 N-(5-Chlorobenzoxazol-2-yl)acetamide 35783-57-4 2 (2-Acetoxyethyl)trimethylammonium hydroxide (Acetylcholine) and its salts 51-84-3 200-128-9 3 Deanol aceglumate (INN) 3342-61-8 222-085-5 4 Spironolactone (INN) 52-01-7 200-133-6 5 [4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid (Tiratricol (INN)) and its salts 51-24-1 200-086-1 6 Methotrexate (INN) 59-05-2 200-413-8 7 Aminocaproic acid (INN) and its salts 60-32-2 200-469-3 8 Cinchophen (INN), its salts, derivatives and salts of these derivatives 132-60-5 205-067-1 9 Thyropropic acid (INN) and its salts 51-26-3 10 Trichloroacetic acid 76-03-9 200-927-2 11 Aconitum napellus L. (leaves, roots and galenical preparations) 84603-50-9 283-252-6 12 Aconitine (principal alkaloid of Aconitum napellus L.) and its salts 302-27-2 206-121-7 13 Adonis vernalis L. and its preparations 84649-73-0 283-458-6 14 Epinephrine (INN) 51-43-4 200-098-7 15 Rauwolfia serpentina L., alkaloids and their salts 90106-13-1 290-234-1 16 Alkyne alcohols, their esters, ethers and salts 17 Isoprenaline (INN) 7683-59-2 231-687-7 18 Allyl isothiocyanate 57-06-7 200-309-2 19 Alloclamide (INN) and its salts 5486-77-1 20 Nalorphine (INN), its salts and ethers 62-67-9 200-546-1 21 Sympathicomimetic amines acting on the central nervous system: any substance contained in the first list of medicaments which are subject to medical prescription and are referred to in resolution AP (69) 2 of the Council of Europe 300-62-9 206-096-2 22 Aniline, its salts and its halogenated and sulphonated derivatives 62-53-3 200-539-3 23 Betoxycaine (INN) and its salts 3818-62-0 24 Zoxazolamine (INN) 61-80-3 200-519-4 25 Procainamide (INN), its salts and derivatives 51-06-9 200-078-8 26 Benzidine 92-87-5 202-199-1 27 Tuaminoheptane (INN), its isomers and salts 123-82-0 204-655-5 28 Octodrine (INN) and its salts 543-82-8 208-851-1 29 2-Amino-1,2-bis(4-methoxyphenyl)ethanol and its salts 530-34-7 30 1,3-Dimethylpentylamine and its salts 105-41-9 203-296-1 31 4-Aminosalicylic acid and its salts 65-49-6 200-613-5 32 Toluidines, their isomers, salts and halogenated and sulphonated derivatives 26915-12-8 248-105-2 33 Xylidines, their isomers, salts and halogenated and sulphonated derivatives 1300-73-8 215-091-4 34 Imperatorin (9-(3-methylbut-2-enyloxy)furo[3,2-g]chromen-7-one) 482-44-0 207-581-1 35 Ammi majus L. and its galenical preparations 90320-46-0 291-072-4 36 2,3-Dichloro-2-methylbutane 507-45-9 37 Substances with androgenic effect 38 Anthracene oil 120-12-7 204-371-1 39 Antibiotics 40 Antimony and its compounds 7440-36-0 231-146-5 41 Apocynum cannabinum L. and its preparations 84603-51-0 283-253-1 42 Apomorphine ((R) 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol) and its salts 58-00-4 200-360-0 43 Arsenic and its compounds 7440-38-2 231-148-6 44 Atropa belladonna L. and its preparations 8007-93-0 232-365-9 45 Atropine, its salts and derivatives 51-55-8 200-104-8 46 Barium salts, with the exception of barium sulphide under the conditions laid down in Annex III, and of barium sulfate, lakes, salts and pigments prepared from colouring agents when listed in Annex IV 47 Benzene 71-43-2 200-753-7 48 Benzimidazol-2(3H)-one 615-16-7 210-412-4 49 Benzazepines and benzodiazepines 12794-10-4 50 1-Dimethylaminomethyl-1-methylpropyl benzoate (amylocaine) and its salts 644-26-8 211-411-1 51 2,2,6-Trimethyl-4-piperidyl benzoate (eucaine) and its salts 500-34-5 52 Isocarboxazid (INN) 59-63-2 200-438-4 53 Bendroflumethiazide (INN) and its derivatives 73-48-3 200-800-1 54 Beryllium and its compounds 7440-41-7 231-150-7 55 Bromine, elemental 7726-95-6 231-778-1 56 Bretylium tosilate (INN) 61-75-6 200-516-8 57 Carbromal (INN) 77-65-6 201-046-6 58 Bromisoval (INN) 496-67-3 207-825-7 59 Brompheniramine (INN) and its salts 86-22-6 201-657-8 60 Benzilonium bromide (INN) 1050-48-2 213-885-5 61 Tetrylammonium bromide (INN) 71-91-0 200-769-4 62 Brucine 357-57-3 206-614-7 63 Tetracaine (INN) and its salts 94-24-6 202-316-6 64 Mofebutazone (INN) 2210-63-1 218-641-1 65 Tolbutamide (INN) 64-77-7 200-594-3 66 Carbutamide (INN) 339-43-5 206-424-4 67 Phenylbutazone (INN) 50-33-9 200-029-0 68 Cadmium and its compounds 7440-43-9 231-152-8 69 Cantharides, Cantharis vesicatoria 92457-17-5 296-298-7 70 Cantharidine 56-25-7 200-263-3 71 Phenprobamate (INN) 673-31-4 211-606-1 72 Nitroderivatives of carbazole 73 Carbon disulphide 75-15-0 200-843-6 74 Catalase 9001-05-2 232-577-1 75 Cephaeline and its salts 483-17-0 207-591-6 76 Chenopodium ambrosioides L. (essential oil) 8006-99-3 77 2,2,2-Trichloroethane-1,1-diol 302-17-0 206-117-5 78 Chlorine 7782-50-5 231-959-5 79 Chlorpropamide (INN) 94-20-2 202-314-5 80 Moved or deleted 81 4-Phenylazophenylene-1,3-diamine citrate hydrochloride (chrysoidine citrate hydrochloride) 5909-04-6 82 Chlorzoxazone (INN) 95-25-0 202-403-9 83 2-Chloro-6-methylpyrimidin-4-yldimethylamine (crimidine-ISO) 535-89-7 208-622-6 84 Chlorprothixene (INN) and its salts 113-59-7 204-032-8 85 Clofenamide (INN) 671-95-4 211-588-5 86 N,N-bis(2-chloroethyl)methylamine N-oxide and its salts 126-85-2 87 Chlormethine (INN) and its salts 51-75-2 200-120-5 88 Cyclophosphamide (INN) and its salts 50-18-0 200-015-4 89 Mannomustine (INN) and its salts 576-68-1 209-404-3 90 Butanilicaine (INN) and its salts 3785-21-5 91 Chlormezanone (INN) 80-77-3 201-307-4 92 Triparanol (INN) 78-41-1 201-115-0 93 2-[2(4-Chlorophenyl)-2-phenylacetyl]indane-1,3-dione (chlorophacinone-ISO) 3691-35-8 223-003-0 94 Chlorphenoxamine (INN) 77-38-3 95 Phenaglycodol (INN) 79-93-6 201-235-3 96 Chloroethane 75-00-3 200-830-5 97 Chromium; chromic acid and its salts 7440-47-3 231-157-5 98 Claviceps purpurea Tul., its alkaloids and galenical preparations 84775-56-4 283-885-8 99 Conium maculatum L. (fruit, powder, galenical preparations) 85116-75-2 285-527-6 100 Glycyclamide (INN) 664-95-9 211-557-6 101 Cobalt benzenesulphonate 23384-69-2 102 Colchicine, its salts and derivatives 64-86-8 200-598-5 103 Colchicoside and its derivatives 477-29-2 207-513-0 104 Colchicum autumnale L. and its galenical preparations 84696-03-7 283-623-2 105 Convallatoxin 508-75-8 208-086-3 106 Anamirta cocculus L. (fruit) 107 Croton tiglium L. (oil) 8001-28-3 108 1-Butyl-3-(N-crotonoylsulphanilyl)urea 52964-42-8 109 Curare and curarine 8063-06-7/22260-42-0 232-511-1/244-880-6 110 Synthetic curarizants 111 Hydrogen cyanide and its salts 74-90-8 200-821-6 112 Feclemine (INN); 2-(alpha-Cyclohexylbenzyl)-N,N,N',N'-tetraethyl-1,3-propanediamine 3590-16-7 113 Cyclomenol (INN) and its salts 5591-47-9 227-002-6 114 Sodium hexacyclonate (INN) 7009-49-6 115 Hexapropymate (INN) 358-52-1 206-618-9 116 Moved or deleted 117 O,O'-Diacetyl-N-allyl-N-normorphine 2748-74-5 118 Pipazetate (INN) and its salts 2167-85-3 218-508-8 119 5-(α,β-Dibromophenethyl)-5-methylhydantoin 511-75-1 208-133-8 120 N,N'-Pentamethylenebis(trimethylammonium) salts, e. g. pentamethonium bromide (INN) 541-20-8 208-771-7 121 N,N'-[(Methylimino)diethylene]bis(ethyldimethylammonium) salts, e. g. azamethonium bromide (INN) 306-53-6 206-186-1 122 Cyclarbamate (INN) 5779-54-4 227-302-7 123 Clofenotane (INN); DDT (ISO) 50-29-3 200-024-3 124 N,N'-Hexamethylenebis(trimethylammonium) salts, e. g. hexamethonium bromide (INN) 55-97-0 200-249-7 125 Dichloroethanes (ethylene chlorides) e.g. 1,2-Dichloroethane 107-06-2 203-458-1 126 Dichloroethylenes (acetylene chlorides) e.g. Vinylidene chloride (1,1-Dichloroethylene) 75-35-4 200-864-0 127 Lysergide (INN) (LSD) and its salts 50-37-3 200-033-2 128 2-Diethylaminoethyl 3-hydroxy-4-phenylbenzoate and its salts 3572-52-9 222-686-2 129 Cinchocaine (INN) and its salts 85-79-0 201-632-1 130 3-Diethylaminopropyl cinnamate 538-66-9 131 O,O'-Diethyl-O-4-nitrophenyl phosphorothioate (Parathion - ISO) 56-38-2 200-271-7 132 [Oxalylbis(iminoethylene)]bis[(o-chlorobenzyl)diethylammonium] salts, e. g. ambenonium chloride (INN) 115-79-7 204-107-5 133 Methyprylon (INN) and its salts 125-64-4 204-745-4 134 Digitaline and all heterosides of Digitalis purpurea L. 752-61-4 212-036-6 135 7-[2-Hydroxy-3-(2-hydroxyethyl-N-methylamino)propyl]theophylline (xanthinol) 2530-97-4 136 Dioxethedrin (INN) and its salts 497-75-6 207-849-8 137 Piprocurarium iodide (INN) 3562-55-8 222-627-0 138 Propyphenazone (INN) 479-92-5 207-539-2 139 Tetrabenazine (INN) and its salts 58-46-8 200-383-6 140 Captodiame (INN) 486-17-9 207-629-1 141 Mefeclorazine (INN) and its salts 1243-33-0 142 Dimethylamine 124-40-3 204-697-4 143 1,1-Bis(dimethylaminomethyl)propyl benzoate (amydricaine, alypine) and its salts 963-07-5 213-512-6 144 Methapyrilene (INN) and its salts 91-80-5 202-099-8 145 Metamfepramone (INN) and its salts 15351-09-4 239-384-1 146 Amitriptyline (INN) and its salts 50-48-6 200-041-6 147 Metformin (INN) and its salts 657-24-9 211-517-8 148 Isosorbide dinitrate (INN) 87-33-2 201-740-9 149 Malononitrile 109-77-3 203-703-2 150 Succinonitrile 110-61-2 203-783-9 151 Dinitrophenol isomers 51-28-5/329-71-5/573-56-8/25550-58-7 200-087-7/206-348-1/209-357-9/247-096-2 152 Inproquone (INN) 436-40-8 153 Dimevamide (INN) and its salts 60-46-8 200-479-8 154 Diphenylpyraline (INN) and its salts 147-20-6 205-686-7 155 Sulfinpyrazone (INN) 57-96-5 200-357-4 156 N-(3-Carbamoyl-3,3-diphenylpropyl)-N,N-diisopropylmethyl-ammonium salts, e. g. isopropamide iodide (INN) 71-81-8 200-766-8 157 Benactyzine (INN) 302-40-9 206-123-8 158 Benzatropine (INN) and its salts 86-13-5 159 Cyclizine (INN) and its salts 82-92-8 201-445-5 160 5,5-Diphenyl-4-imidazolidone (Doxenitoin (INN)) 3254-93-1 221-851-6 161 Probenecid (INN) 57-66-9 200-344-3 162 Disulfiram (INN); thiram (INN) 97-77-8/137-26-8 202-607-8/205-286-2 163 Emetine, its salts and derivatives 483-18-1 207-592-1 164 Ephedrine and its salts 299-42-3 206-080-5 165 Oxanamide (INN) and its derivatives 126-93-2 166 Eserine or physostigmine and its salts 57-47-6 200-332-8 ▼M1 167 4-Aminobenzoic acid and its esters, with the free amino group 150-13-0 205-753-0 ▼B 168 Choline salts and their esters, e. g. choline chloride (INN) 67-48-1 200-655-4 169 Caramiphen (INN) and its salts 77-22-5 201-013-6 170 Diethyl 4-nitrophenyl phosphate (Paraoxon - ISO) 311-45-5 206-221-0 171 Metethoheptazine (INN) and its salts 509-84-2 172 Oxpheneridine (INN) and its salts 546-32-7 173 Ethoheptazine (INN) and its salts 77-15-6 201-007-3 174 Metheptazine (INN) and its salts 469-78-3 175 Methylphenidate (INN) and its salts 113-45-1 204-028-6 176 Doxylamine (INN) and its salts 469-21-6 207-414-2 177 Tolboxane (INN) 2430-46-8 178 4-Benzyloxyphenol and 4-ethoxyphenol 103-16-2/622-62-8 203-083-3/210-748-1 179 Parethoxycaine (INN) and its salts 94-23-5 205-246-4 180 Fenozolone (INN) 15302-16-6 239-339-6 181 Glutethimide (INN) and its salts 77-21-4 201-012-0 182 Ethylene oxide 75-21-8 200-849-9 183 Bemegride (INN) and its salts 64-65-3 200-588-0 184 Valnoctamide (INN) 4171-13-5 224-033-7 185 Haloperidol (INN) 52-86-8 200-155-6 186 Paramethasone (INN) 53-33-8 200-169-2 187 Fluanisone (INN) 1480-19-9 216-038-8 188 Trifluperidol (INN) 749-13-3 189 Fluoresone (INN) 2924-67-6 220-889-0 190 Fluorouracil (INN) 51-21-8 200-085-6 191 Hydrofluoric acid, its normal salts, its complexes and hydrofluorides with the exception of those given in Annex III 7664-39-3 231-634-8 192 Furfuryltrimethylammonium salts, e. g. furtrethonium iodide (INN) 541-64-0 208-789-5 193 Galantamine (INN) 357-70-0 194 Progestogens 195 1,2,3,4,5,6-Hexachlorocyclohexane (BHC-ISO) 58-89-9 200-401-2 196 (1R,4S,5R,8S)-1,2,3,4,10,10-Hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4:5,8-dimethano-naphthalene (endrin-ISO) 72-20-8 200-775-7 197 Hexachloroethane 67-72-1 200-666-4 198 (1R,4S,5R,8S)-1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene (isodrin-ISO) 465-73-6 207-366-2 199 Hydrastine, hydrastinine and their salts 118-08-1/6592-85-4 204-233-0/229-533-9 200 Hydrazides and their salts e.g. Isoniazid (INN) 54-85-3 200-214-6 201 Hydrazine, its derivatives and their salts 302-01-2 206-114-9 202 Octamoxin (INN) and its salts 4684-87-1 203 Warfarin (INN) and its salts 81-81-2 201-377-6 204 Ethyl bis(4-hydroxy-2-oxo-1-benzopyran-3-yl)acetate and salts of the acid 548-00-5 208-940-5 205 Methocarbamol (INN) 532-03-6 208-524-3 206 Propatylnitrate (INN) 2921-92-8 220-866-5 207 4,4'-Dihydroxy-3,3'-(3-methylthiopropylidene) dicoumarin 208 Fenadiazole (INN) 1008-65-7 209 Nitroxoline (INN) and its salts 4008-48-4 223-662-4 210 Hyoscyamine, its salts and derivatives 101-31-5 202-933-0 211 Hyoscyamus niger L. (leaves, seeds, powder and galenical preparations) 84603-65-6 283-265-7 212 Pemoline (INN) and its salts 2152-34-3 218-438-8 213 Iodine 7553-56-2 231-442-4 214 Decamethylenebis(trimethylammonium) salts, e. g. decamethonium bromide (INN) 541-22-0 208-772-2 215 Ipecacuanha (Cephaelis ipecacuanha Brot. and related species) (roots, powder and galenical preparations) 8012-96-2 232-385-8 216 (2-Isopropylpent4-enoyl)urea (apronalide) 528-92-7 208-443-3 217 α-Santonin [(3S,5aR,9bS)-3,3a,4,5,5a,9b-hexahydro-3,5a,9-trimethylnaphto [1,2-b] furan-2,8-dione] 481-06-1 207-560-7 218 Lobelia inflata L. and its galenical preparations 84696-23-1 283-642-6 219 Lobeline (INN) and its salts 90-69-7 202-012-3 220 Barbiturates 221 Mercury and its compounds, except those special cases included in Annex V 7439-97-6 231-106-7 222 3,4,5-Trimethoxyphenethylamine (Mescaline) and its salts 54-04-6 200-190-7 223 Metaldehyde 9002-91-9 224 2-(4-Allyl-2-methoxyphenoxy)-N,N-diethylacetamide and its salts 305-13-5 225 Coumetarol (INN) 4366-18-1 224-455-1 226 Dextromethorphan (INN) and its salts 125-71-3 204-752-2 227 2-Methylheptylamine and its salts 540-43-2 228 Isometheptene (INN) and its salts 503-01-5 207-959-6 229 Mecamylamine (INN) 60-40-2 200-476-1 230 Guaifenesin (INN) 93-14-1 202-222-5 231 Dicoumarol (INN) 66-76-2 200-632-9 232 Phenmetrazine (INN), its derivatives and salts 134-49-6 205-143-4 233 Thiamazole (INN) 60-56-0 200-482-4 234 3,4-Dihydro-2-methoxy-2-methyl-4-phenyl-2H,5H-pyrano [3,2-c]-[1] benzopyran-5-one (cyclocoumarol) 518-20-7 208-248-3 235 Carisoprodol (INN) 78-44-4 201-118-7 236 Meprobamate (INN) 57-53-4 200-337-5 237 Tefazoline (INN) and its salts 1082-56-0 238 Arecoline 63-75-2 200-565-5 239 Poldine metilsulfate (INN) 545-80-2 208-894-6 240 Hydroxyzine (INN) 68-88-2 200-693-1 241 2-Naphthol 135-19-3 205-182-7 242 1-and 2-Naphthylamines and their salts 134-32-7/91-59-8 205-138-7/202-080-4 243 3-(1-Naphthyl)-4-hydroxycoumarin 39923-41-6 244 Naphazoline (INN) and its salts 835-31-4 212-641-5 245 Neostigmine and its salts e. g. neostigmine bromide (INN) 114-80-7 204-054-8 246 Nicotine and its salts 54-11-5 200-193-3 247 Amyl nitrites 110-46-3 203-770-8 248 Inorganic nitrites, with the exception of sodium nitrite 14797-65-0 249 Nitrobenzene 98-95-3 202-716-0 250 Nitrocresols and their alkali metal salts 12167-20-3 251 Nitrofurantoin (INN) 67-20-9 200-646-5 252 Furazolidone (INN) 67-45-8 200-653-3 253 Nitroglycerin; Propane-1,2,3-triyl trinitrate 55-63-0 200-240-8 254 Acenocoumarol (INN) 152-72-7 205-807-3 255 Alkali pentacyanonitrosylferrate (2-) e.g. 14402-89-2/13755-38-9 238-373-9 / - 256 Nitrostilbenes, their homologues and their derivatives 257 Noradrenaline and its salts 51-41-2 200-096-6 258 Noscapine (INN) and its salts 128-62-1 204-899-2 259 Guanethidine (INN) and its salts 55-65-2 200-241-3 260 Oestrogens 261 Oleandrin 465-16-7 207-361-5 262 Chlortalidone (INN) 77-36-1 201-022-5 263 Pelletierine and its salts 2858-66-4/4396-01-4 220-673-6/224-523-0 264 Pentachloroethane 76-01-7 200-925-1 265 Pentaerithrityl tetranitrate (INN) 78-11-5 201-084-3 266 Petrichloral (INN) 78-12-6 267 Octamylamine (INN) and its salts 502-59-0 207-947-0 268 Picric acid 88-89-1 201-865-9 269 Phenacemide (INN) 63-98-9 200-570-2 270 Difencloxazine (INN) 5617-26-5 271 2-Phenylindan-1,3-dione (phenindione (INN)) 83-12-5 201-454-4 272 Ethylphenacemide (pheneturide (INN)) 90-49-3 201-998-2 273 Phenprocoumon (INN) 435-97-2 207-108-9 274 Fenyramidol (INN) 553-69-5 209-044-7 275 Triamterene (INN) and its salts 396-01-0 206-904-3 276 Tetraethyl pyrophosphate (TEPP - ISO) 107-49-3 203-495-3 277 Tritolyl phosphate 1330-78-5 215-548-8 278 Psilocybine (INN) 520-52-5 208-294-4 279 Phosphorus and metal phosphides 7723-14-0 231-768-7 280 Thalidomide (INN) and its salts 50-35-1 200-031-1 281 Physostigma venenosum Balf. 89958-15-6 289-638-0 282 Picrotoxin 124-87-8 204-716-6 283 Pilocarpine and its salts 92-13-7 202-128-4 284 α-Piperidin-2-ylbenzyl acetate, laevorotatory threoform (levofacetoperane (INN)) and its salts 24558-01-8 285 Pipradrol (INN) and its salts 467-60-7 207-394-5 286 Azacyclonol (INN) and its salts 115-46-8 204-092-5 287 Bietamiverine (INN) 479-81-2 207-538-7 288 Butopiprine (INN) and its salts 55837-15-5 259-848-7 289 Lead and its compounds 7439-92-1 231-100-4 290 Coniine 458-88-8 207-282-6 291 Prunus laurocerasus L. (‘cherry laurel water’) 89997-54-6 289-689-9 292 Metyrapone (INN) 54-36-4 200-206-2 293 Radioactive substances, as defined by Directive 96/29/Euratom (1) laying down basic safety standards for the protection of the health of workers and the general public against the dangers arising from ionising radiation 294 Juniperus sabina L. (leaves, essential oil and galenical preparations) 90046-04-1 289-971-1 295 Hyoscine, its salts and derivatives 51-34-3 200-090-3 296 Gold salts 297 Selenium and its compounds with the exception of selenium disulphide under the conditions set out under reference No 49 in Annex III 7782-49-2 231-957-4 298 Solanum nigrum L. and its galenical preparations 84929-77-1 284-555-6 299 Sparteine (INN) and its salts 90-39-1 201-988-8 300 Glucocorticoids (Corticosteroids) 301 Datura stramonium L. and its galenical preparations 84696-08-2 283-627-4 302 Strophantines, their aglucones and their respective derivatives 11005-63-3 234-239-9 303 Strophantus species and their galenical preparations 304 Strychnine and its salts 57-24-9 200-319-7 305 Strychnos species and their galenical preparations 306 Narcotics, natural and synthetic: All substances listed in Tables I and II of the single Convention on narcotic drugs signed in New York on 30 March 1961 307 Sulphonamides (sulphanilamide and its derivatives obtained by substitution of one or more H-atoms of the -NH2 groups) and their salts 308 Sultiame (INN) 61-56-3 200-511-0 309 Neodymium and its salts 7440-00-8 231-109-3 310 Thiotepa (INN) 52-24-4 200-135-7 311 Pilocarpus jaborandi Holmes and its galenical preparations 84696-42-4 283-649-4 312 Tellurium and its compounds 13494-80-9 236-813-4 313 Xylometazoline (INN) and its salts 526-36-3 208-390-6 314 Tetrachloroethylene 127-18-4 204-825-9 315 Carbon tetrachloride 56-23-5 200-262-8 316 Hexaethyl tetraphosphate 757-58-4 212-057-0 317 Thallium and its compounds 7440-28-0 231-138-1 318 Thevetia neriifolia Juss., glycoside extract 90147-54-9 290-446-4 319 Ethionamide (INN) 536-33-4 208-628-9 320 Phenothiazine (INN) and its compounds 92-84-2 202-196-5 321 Thiourea and its derivatives, with the exception of the one listed in Annex III 62-56-6 200-543-5 322 Mephenesin (INN) and its esters 59-47-2 200-427-4 323 Vaccines, toxins or serums defined as immunological medicinal products pursuant to Article 1(4) of Directive 2001/83/EC 324 Tranylcypromine (INN) and its salts 155-09-9 205-841-9 325 Trichloronitromethane (chloropicrine) 76-06-2 200-930-9 326 2,2,2-Tribromoethanol (tribromoethyl alcohol) 75-80-9 200-903-1 327 Trichlormethine (INN) and its salts 817-09-4 212-442-3 328 Tretamine (INN) 51-18-3 200-083-5 329 Gallamine triethiodide (INN) 65-29-2 200-605-1 330 Urginea scilla Steinh. and its galenical preparations 84650-62-4 283-520-2 331 Veratrine, its salts and galenical preparations 8051-02-3 613-062-00-4 332 Schoenocaulon officinale Lind (seeds and galenical preparations) 84604-18-2 283-296-6 333 Veratrum spp. and their preparations 90131-91-2 290-407-1 334 Vinyl chloride monomer 75-01-4 200-831-0 335 Ergocalciferol (INN) and cholecalciferol (vitamins D2 and D3) 50-14-6/67-97-0 200-014-9/200-673-2 336 Salts of O-alkyldithiocarbonic acids (xanthates) 337 Yohimbine and its salts 146-48-5 205-672-0 338 Dimethyl sulfoxide (INN) 67-68-5 200-664-3 339 Diphenhydramine (INN) and its salts 58-73-1 200-396-7 340 4-tert-Butylphenol 98-54-4 202-679-0 341 4-tert-Butylpyrocatechol 98-29-3 202-653-9 342 Dihydrotachysterol (INN) 67-96-9 200-672-7 343 Dioxane 123-91-1 204-661-8 344 Morpholine and its salts 110-91-8 203-815-1 345. Pyrethrum album L. and its galenical preparations 346 2-[4-Methoxybenzyl-N-(2-pyridyl)amino]ethyldimethylamine maleate (Mepyramine maleate; pyrilamine maleate) 59-33-6 200-422-7 347 Tripelennamine (INN) 91-81-6 202-100-1 348 Tetrachlorosalicylanilides 7426-07-5 349 Dichlorosalicylanilides 1147-98-4 350 Tetrabromosalicylanilides 351 Dibromosalicylanilides 352 Bithionol (INN) 97-18-7 202-565-0 353 Thiuram monosulphides 97-74-5 202-605-7 354 Moved or deleted 355 Dimethylformamide (N,N-Dimethylformamide) 68-12-2 200-679-5 356 4-Phenylbut-3-en-2-one (Benzylidene acetone) 122-57-6 204-555-1 357 Benzoates of 4-hydroxy-3-methoxycinnamyl alcohol (coniferyl alcohol) except for normal content in natural essences used 358 Furocoumarines (e. g. trioxysalen (INN), 8-methoxypsoralen, 5-methoxypsoralen) except for normal content in natural essences used. In sun protection and in bronzing products, furocoumarines shall be below 1 mg/kg 3902-71-4/298-81-7/484-20-8 223-459-0/206-066-9/207-604-5 359 Oil from the seeds of Laurus nobilis L. 84603-73-6 283-272-5 360 Safrole except for normal content in the natural essences used and provided the concentration does not exceed: 100 ppm in the finished product, 50 ppm in products for dental and oral hygiene, and provided that Safrole is not present in toothpastes intended specifically for children 94-59-7 202-345-4 361 5,5'-Di-isopropyl-2,2'-dimethylbiphenyl-4,4'-diyl dihypoiodite (thymol iodide) 552-22-7 209-007-5 362 3'-Ethyl-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-acetonaphthone or 7-acetyl-6-ethyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphtalen (AETT; Versalide) 88-29-9 201-817-7 363 o-Phenylenediamine and its salts 95-54-5 202-430-6 364 4-Methyl-m-phenylenediamine (Toluene-2,4-diamine) and its salts 95-80-7 202-453-1 365 Aristolochic acid and its salts; Aristolochia spp. and their preparations 475-80-9/313-67-7/15918-62-4 202-499-6/206-238-3/- 366 Chloroform 67-66-3 200-663-8 367 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 1746-01-6 217-122-7 368 2,6-Dimethyl-1,3-dioxan-4-yl acetate (Dimethoxane) 828-00-2 212-579-9 369 Pyrithione sodium (INNM) (2) 3811-73-2 223-296-5 370 N-(Trichloromethylthio)-4-cyclohexene-1,2-dicarboximide (Captan - ISO) 133-06-2 205-087-0 371 2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane (Hexachlorophene (INN)) 70-30-4 200-733-8 372 6-(Piperidinyl)-2,4-pyrimidinediamine 3-oxide (Minoxidil (INN)) and its salts 38304-91-5 253-874-2 373 3,4',5-Tribromosalicylanilide (Tribromsalan (INN)) 87-10-5 201-723-6 374 Phytolacca spp. and their preparations 65497-07-6/60820-94-2 375 Tretinoin (INN) (retinoic acid and its salts) 302-79-4 206-129-0 376 1-Methoxy-2,4-diaminobenzene (2,4-diaminoanisole - CI 76050) and its salts 615-05-4 210-406-1 377 1-Methoxy-2,5-diaminobenzene (2,5-diaminoanisole) and its salts 5307-02-8 226-161-9 378 Colouring agent CI 12140 3118-97-6 221-490-4 379 Colouring agent CI 26105 (Solvent Red 24) 85-83-6 201-635-8 380 Colouring agent CI 42555 (Basic Violet 3) Colouring agent CI 42555:1 Colouring agent CI 42555:2 548-62-9 467-63-0 208-953-6 207-396-6 381 Amyl 4-dimethylaminobenzoate, mixed isomers (Padimate A (INN)) 14779-78-3 238-849-6 383 2-Amino-4-nitrophenol 99-57-0 202-767-9 384 2-Amino-5-nitrophenol 121-88-0 204-503-8 385 11-α-Hydroxypregn-4-ene-3,20-dione and its esters 80-75-1 201-306-9 386 Colouring agent CI 42640 ([4-[[4-(Dimethylamino)phenyl][4-[ethyl(3-sulphonatobenzyl)amino]phenyl]methylene]cyclohexa-2,5-dien-1-ylidene](ethyl)(3-sulphonatobenzyl)ammonium, sodium salt) 1694-09-3 216-901-9 387 Colouring agent CI 13065 587-98-4 209-608-2 388 Colouring agent CI 42535 (Basic Violet 1) 8004-87-3 389 Colouring agent CI 61554 (Solvent Blue 35) 17354-14-2 241-379-4 390 Anti-androgens of steroidal structure 391 Zirconium and its compounds, with the exception of the substances listed under reference number 50 in Annex III, and the zirconium lakes, pigments or salts of the colouring agents when listed in Annex IV 7440-67-7 231-176-9 392 Moved or deleted 393 Acetonitrile 75-05-8 200-835-2 394 Tetrahydrozoline (Tetryzoline (INN)) and its salts 84-22-0 201-522-3 395 Hydroxy-8-quinoline and its sulphate, except for the uses provided for in No 51 in Annex III 148-24-3/134-31-6 205-711-1/205-137-1 396 Dithio-2,2-bispyridine-dioxide 1,1' (additive with trihydrated magnesium sulphate) - (pyrithione disulphide + magnesium sulphate) 43143-11-9 256-115-3 397 Colouring agent CI 12075 (Pigment Orange 5) and its lakes, pigments and salts 3468-63-1 222-429-4 398 Colouring agent CI 45170 and CI 45170:1 (Basic Violet 10) 8